BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma

Human Pathology

Volumn 46, Issue 11, 2015, Pages 1670-1678

  McGregor, Stephanie M ^a   Dunning, Ryan ^a   Hyjek, Elizabeth ^a   Vigneswaran, Wickii ^a   Husain, Aliya N ^a   Krausz, Thomas ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

BAP1 immunohistochemistry; Diagnosis; Histologic classification; Malignant pleural mesothelioma; Prognosis

Indexed keywords

BRCA ASSOCIATED PROTEIN 1; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG; BAP1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PREDICTIVE VALUE; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; TUMOR CLASSIFICATION; VERY ELDERLY; DIFFERENTIAL DIAGNOSIS; EPITHELIUM; LUNG NEOPLASMS; MESOTHELIOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; PLEURAL NEOPLASMS; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; DIAGNOSIS, DIFFERENTIAL; EPITHELIUM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; PROGNOSIS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE;

EID: 84945474644     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2015.06.024     Document Type: Article

References (33)

1. A.N. Husain, T. Colby, N. Ordonez, and et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the international mesothelioma interest group Arch Pathol Lab Med 137 2013 647 667
2. A. Churg, and F. Galateau-Sallé The separation of benign and malignant mesothelial proliferations Arch Pathol Lab Med 136 2012 1217 1226
3. N. van Zandwijk, C. Clarke, D. Henderson, and et al. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma J Thorac Dis 5 2013 E254 E307
4. J.D.V. Dognini, and E.A.S. Melis Malignant pleural mesothelioma: management and role of radiation therapy J Nucl Med Radiat Ther 2013 1 6
5. B. Balduyck, D. Trousse, A. Nakas, A.E. Martin-Ucar, J. Edwards, and D.A. Waller Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile? Ann Thorac Surg 89 2010 907 911
6. W.D. Travis, E. Brambilla, A.P. Burke, A. Marks, and A.G. Nicholson World Health Organization classification of tumours of the lung, pleura, thymus and heart 4th ed. 2015 IARC Press Lyon
7. G. Guo, J. Chmielecki, C. Goparaju, and et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma Cancer Res 75 2015 264 269
8. M. Lo Iacono, V. Monica, L. Righi, and et al. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma J Thorac Oncol 2014 1 62
9. Y. Yoshikawa, A. Sato, T. Tsujimura, and et al. Biallelic germline and somatic mutations in malignant mesothelioma: multiple mutations in transcription regulators including mSWI/SNF genes Int J Cancer 136 2015 560 571
10. M. Bott, M. Brevet, B.S. Taylor, and et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma Nat Genet 43 2011 668 672
11. J.R. Testa, M. Cheung, J. Pei, and et al. Germline BAP1 mutations predispose to malignant mesothelioma Nat Genet 43 2011 1022 1025
12. M.G. Zauderer, M. Bott, R. McMillan, and et al. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations J Thorac Oncol 8 2013 1430 1433
13. C. Ribeiro, S. Campelos, C.S. Moura, J.C. Machado, A. Justino, and B. Parente Well-differentiated papillary mesothelioma: clustering in a Portuguese family with a germline BAP1 mutation Ann Oncol 24 2013 2147 2150
14. F. Baumann, E. Flores, A. Napolitano, and et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival Carcinogenesis 36 2015 76 81
15. M. Betti, E. Casalone, D. Ferrante, and et al. Inference on germline BAP1mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area Genes Chromosomes Cancer 54 2014 51 62
16. A. Rusch, G. Ziltener, K. Nackaerts, W. Weder, R.A. Stahel, and E. Felley-Bosco Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases Lung Cancer 87 2015 77 79
17. M. Cheung, J. Talarchek, K. Schindeler, and et al. Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma Cancer Genetics 206 2013 206 210
18. L. Arzt, F. Quehenberger, I. Halbwedl, T. Mairinger, and H.H. Popper BAP1 protein is a progression factor in malignant pleural mesothelioma Pathol Oncol Res 20 2013 145 151
19. Y. Yoshikawa, A. Sato, T. Tsujimura, and et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma Cancer Sci 103 2012 868 874
20. M. Ladanyi, M.G. Zauderer, L.M. Krug, and et al. New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment Clin Cancer Res 18 2012 4485 4490
21. A.N. Husain, M.K. Mirza, A. Gibbs, and et al. How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study Lung Cancer 83 2014 324 328
22. C. Pinheiro, A. Longatto-Filho, T.R. Soares, and et al. CD147 immunohistochemistry discriminates between reactive mesothelial cells and malignant mesothelioma Diagn Cytopathol 40 2012 478 483
23. A. Sato, I. Torii, Y. Okamura, and et al. Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium Mod Pathol 23 2010 1458 1466
24. M. Ladanyi Implications of P16/CDKN2A deletion in pleural mesotheliomas Lung Cancer 49 2005 S95 S98
25. S. Chiosea, A. Krasinskas, P.T. Cagle, K.A. Mitchell, D.S. Zander, and S. Dacic Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas Mod Pathol 21 2008 742 747
26. R.E. Factor, P. Dal Cin, J.A. Fletcher, and E.S. Cibas Cytogenetics and fluorescence in situ hybridization as adjuncts to cytology in the diagnosis of malignant mesothelioma Cancer Cytopathol 117 2009 247 253
27. S. Savic, N. Franco, B. Grilli, and et al. Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology Chest 2010 1 8
28. M. Takeda, T. Kasai, Y. Enomoto, and et al. 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis Pathol Int 60 2010 395 399
29. C.T.S. Chung, G.D.C. Santos, D.M. Hwang, and et al. FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma J Clin Pathol 63 2010 630 634
30. D. Wu, K. Hiroshima, S. Matsumoto, and et al. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis Am J Clin Pathol 139 2012 39 46
31. B.S. Sheffield, H.C. Hwang, A.F. Lee, and et al. BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations Am J Surg Pathol 2015 1
32. S. McGregor, A. Minor, C. Fitzpatrick, and et al. Combined use of p16 FISH and BAP1 immunohistochemistry optimizes diagnosis of malignant pleural mesothelioma [Abstract 1913] Mod Pathol 26 Suppl. 2 2013 460A
33. S.C.-H. Kao, T.D. Yan, K. Lee, and et al. Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma J Thorac Oncol 6 2011 602 605